EAM Investors’s bluebird bio BLUE Stock Holding History

EAM Investors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-895	Closed	-$1.98M	–	296
2018 Q1	$1.98M	Sell	895 -501	-36%	-$1.27M	0.33%	142
2017 Q4	$3.22M	Sell	1,396 -18	-1%	-$36.5K	0.58%	37
2017 Q3	$2.52M	Buy	+1,414	New	+$1.98M	0.33%	107
2016 Q4	–	Sell	-3,196	Closed	-$2.81M	–	318
2016 Q3	$2.81M	Buy	+3,196	New	+$2.32M	0.38%	131
2015 Q3	–	Sell	-1,582	Closed	-$3.45M	–	297
2015 Q2	$3.45M	Sell	1,582 -1,792	-53%	-$3.65M	0.4%	85
2015 Q1	$5.28M	Sell	3,374 -1,380	-29%	-$1.82M	0.61%	12
2014 Q4	$5.65M	Buy	4,754 +2,485	+110%	+$1.66M	0.79%	6
2014 Q3	$1.05M	Buy	2,269 +531	+31%	+$245K	0.21%	248
2014 Q2	$868K	Buy	+1,738	New	+$557K	0.16%	303

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's BLUE Position: Q2 2018 in Review

EAM Investors sold out of bluebird bio (BLUE) in Q2 2018, closing a stake of 895 shares — an estimated $1.98M sold.

EAM Investors first reported a position in BLUE in Q2 2014 and held it in 9 quarters. The position peaked at $5.65M in Q4 2014. 307 funds tracked by Wall St. Rank hold BLUE as of Q2 2018.

EAM Investors reported no remaining bluebird bio position as of Q2 2018 after selling out during the quarter.
EAM Investors sold 895 bluebird bio shares in Q2 2018, an estimated $1.98M.
EAM Investors first reported a position in bluebird bio in Q2 2014 and held it in 9 quarters.
EAM Investors's bluebird bio position peaked at $5.65M in Q4 2014.
307 funds tracked by Wall St. Rank held bluebird bio as of Q2 2018.

Based on EAM Investors's 13F filing for Q2 2018, filed 3 Aug 2018.